Abstract

Investment in vaccine product development should be guided by up-to-date and transparent global burden of disease estimates, which are also fundamental to policy recommendation and vaccine introduction decisions. For low- and middle-income countries (LMICs), vaccine prioritization is primarily driven by the number of deaths caused by different pathogens. Enteric diseases are known to be a major cause of death in LMICs. The two main modelling groups providing mortality estimates for enteric diseases are the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, Seattle and the Maternal Child Epidemiology Estimation (MCEE) group, led by Johns Hopkins Bloomberg School of Public Health. Whilst previous global diarrhoea mortality estimates for under five-year-olds from these two groups were closely aligned, more recent estimates for 2016 have diverged, particularly with respect to numbers of deaths attributable to different enteric pathogens. This has impacted prioritization and investment decisions for vaccines in the development pipeline.The mission of the Product Development for Vaccines Advisory Committee (PDVAC) at the World Health Organisation (WHO) is to accelerate product development of vaccines and technologies that are urgently needed and ensure they are appropriately targeted for use in LMICs. At their 2018 meeting, PDVAC recommended the formation of an independent working group of subject matter experts to explore the reasons for the difference between the IHME and MCEE estimates, and to assess the respective strengths and limitations of the estimation approaches adopted, including a review of the data on which the estimates are based.Here, we report on the proceedings and recommendations from a consultation with the working group of experts, the IHME and MCEE modelling groups, and other key stakeholders. We briefly review the methodological approaches of both groups and provide a series of proposals for investigating the drivers for the differences in enteric disease burden estimates.

Highlights

  • Whilst it is estimated that diarrhoeal mortality has decreased by more than 20% from the decade between 2005 and 2015, the burden of diarrhoea is still significant and predominantly affects sub-Saharan Africa and South Asia in populations with poor access to primary healthcare, clean water and sanitation [1].Today, diarrhoeal diseases with the highest burden in under five-year olds are considered to be rotavirus, Shigella and Salmonella species

  • Reference will be made to two large landmark epidemiology studies, namely the Global Enteric Multicentre Study of Diarrheal Disease (GEMS) [15] and the Aetiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development study (MAL-ED) [16]

  • Maternal Child Epidemiology Estimation (MCEE) considers mortality attribution may be a result of multiple pathogens, but they do constrain the pathogen prevalence envelope to add up to 1 minus the proportion of diarrhoea without a known cause

Read more

Summary

Introduction

Whilst it is estimated that diarrhoeal mortality has decreased by more than 20% from the decade between 2005 and 2015, the burden of diarrhoea is still significant and predominantly affects sub-Saharan Africa and South Asia in populations with poor access to primary healthcare, clean water and sanitation [1].Today, diarrhoeal diseases with the highest burden in under five-year olds are considered to be rotavirus, Shigella and Salmonella species. In 1975, the WHO recommended oral rehydration solution globally as the standard immediate treatment for acute diarrhea [2], yet recent evidence suggests that recognition by caregivers may be poor, and uptake remains low [3]. The routine use of antimicrobials for diarrhoea in children is only recommended by WHO in clinically severe cases for cholera, shigellosis, dysenteric presentation of campylobacteriosis and non-typhoidal salmonellosis, or when the host immune status is severely compromised by severe malnutrition or chronic disease [4]. Future research and development of vaccines against diarrhoeal pathogens have been highlighted as key priorities to reduce global disease burden [8,9]. There are currently licensed vaccines for rotavirus and cholera; vaccines are not currently available for any of the other major diarrhoeal pathogens, all have candidates in clinical development

Objectives
Methods
Findings
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call